RxDoctor Payments DataLook up a doctor →

John Stoukides, MD

Geriatric Medicine · East Providence, RINPI 1639176357

Payments from drug & device makers

$6,543,833in general payments, 2019–2025

Across 501 payments — averaging $13,062 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$2.7M
  • Eisai Inc.$1.6M
  • Biogen$1.4M
  • Genentech, Inc.$400K
  • Novartis$212K
  • E.r. Squibb & Sons, L.L.C.$52K
  • plus $69K from 8 others
$19,464in research payments, 2019–2025

Across 8 payments — averaging $2432.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$19K

What the payments were for

  • Consulting fees$1,50045%
  • Travel & lodging$1,23537%
  • Food & beverage$55217%
  • Education$411%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,543,833 in reported general payments places this provider in the 95th percentile of 28 geriatric medicine providers in Rhode Island.

See all geriatric medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$59,940
Medicare patients
186
Services billed
738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban375$171,376
XareltoRivaroxaban159$78,160
Aminocaproic Acid23$39,911
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$23,614
JardianceEmpagliflozin39$21,740
Rivastigmine93$21,142
Lacosamide25$19,813
Spiriva RespimatTiotropium Bromide28$15,189
Incruse ElliptaUmeclidinium Bromide54$14,734
Atorvastatin Calcium888$14,469
TradjentaLinagliptin36$14,393
Trazodone Hcl820$13,989
Mirtazapine340$11,480
Quetiapine Fumarate404$10,849
JanuviaSitagliptin Phosphate28$10,554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$171,376375 claims
Johnson & JohnsonXarelto$99$78,160159 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$22$51,323103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 geriatric medicine providers in Rhode Island.

Other geriatric medicine in East Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →